



HIV Antigen (Antibody) Seroconversion Panel Donor No. 63602

(Catalog No. ANT 6247)

For Research Use Only

Application Notes: This HIV “Antigen” Seroconversion Panel was first identified and “captured” from a plasma donor during the HIV Seroconversion event with the use of **HIV P24 Ag screening tests**. You will notice that this Panel shares many of the same characteristics as HIV antibody Seroconversion Panels except that this donor was identified *earlier in the Seroconversion window*. “Panels” of characterized patient sera have become a well recognized and important element in today’s *in vitro* diagnostic test kit research, product development and clinical trials. This HIV Antigen Seroconversion Panel is a ten member series of specimens collected longitudinally from a *thirty-six year old African American male* plasma donor.

Panel Member	Bleed Date	ALT Normal Range (10-45 u/L)	ABBOTT HIV 1 p24 Ag Lab #1	ABBOTT HIV 1 p24 Ag Lab #2	ABBOTT HIV Ag Monoclonal NT%	ABBOTT Anti-HIV 1/2 EIA	ABBOTT Anti-HIV 1/2 3rd Generation EIA Plus	ABBOTT AxSYM Anti-HIV 1/2	ORTHO Anti-HIV 1/2 Enhanced ELISA	BOEHRINGER MANNHEIM Enzygnost Anti-HIV 1/2 Plus Subtype 0
6247-01	03/15/97	3	0.371	0.03	neg.	0.076	0.25	0.41	0.02	0.34
6247-02	03/17/97	7	0.290	0.03	neg.	0.085	0.20	0.42	0.02	0.34
6247-03	03/22/97	4	0.387	0.03	neg.	0.076	0.26	0.40	0.02	0.34
6247-04	03/24/97	5	0.387	0.32	neg.	0.076	0.24	0.40	0.02	0.34
6247-05	03/29/97	10	0.339	0.28	neg.	0.119	0.40	0.43	0.02	0.34
6247-06	03/31/97	7	0.355	0.34	neg.	0.119	0.23	0.38	0.02	0.33
6247-07	04/05/97	11	0.290	0.92	neg.	0.110	0.22	0.38	0.02	0.34
6247-08	04/07/97	7	1.113	1.89	105.30	0.153	0.20	0.38	0.02	0.33
6247-09	04/12/97	10	7.242	20.73	97.60	0.254	0.33	0.37	0.02	0.34
6247-10	04/14/97	13	11.823	20.76	95.79	3.534	3.02	1.64	0.04	0.34

Notes on Data: Data is presented as an S/Co ratio. Ratios > 1.0 are considered reactive. This panel is for investigational use only and the data is offered for informational purposes only. Data is generated at ZeptoMetrix Corporation and by our Lab Partners in the United States and Europe.

We will endeavor to update our data sheets whenever new test data becomes available to us. All specimens collected in this longitudinal series are naturally occurring, undiluted, unprocessed samples, collected from a single plasma donor in the United States. No preservatives have been added.

More Data ➔

Antigen Seroconversion Panel

(Catalog No. ANT 6247)

Donor No. 63602

Page 2 of 2

Panel Member	Bleed Date	COULTER HIV 1 p24 Ag Lab#1	COULTER HIV 1 p24 Antigen NT%	ROCHE DIAGNOSTIC Cobas Anti-HIV 1 / 2 EIA	WALDHEIM DIAGNOSTICA FLUOROGNOST Anti-HIV 1	BIOTEST Anti-HIV 1 / 2	ORGANON Vironostika Uni-form II Plus O	SANOFI Genscreen Anti-HIV 1 / 2
6247-01	03/15/97	0.255	0.087	0.05	neg.	0.14	0.31	0.24
6247-02	03/17/97	0.373	0.072	0.06	neg.	0.12	0.29	0.13
6247-03	03/22/97	0.343	0.087	0.06	neg.	0.18	0.31	0.16
6247-04	03/24/97	0.343	0.087	0.05	neg.	0.14	0.31	0.10
6247-05	03/29/97	0.294	0.072	0.05	neg.	0.14	0.31	0.19
6247-06	03/31/97	0.275	0.087	0.05	neg.	0.11	0.33	0.14
6247-07	04/05/97	1.265	1.130	0.06	neg.	0.15	0.31	0.19
6247-08	04/07/97	8.598	8.681	0.05	neg.	0.13	0.33	0.14
6247-09	04/12/97	37.618	36.232	0.06	neg.	0.16	0.42	0.22
6247-10	04/14/97	39.941	36.232	0.06	neg.	0.62	1.03	0.35

Panel Member	Bleed Date	BEHRINGWERKE Enzygnost Anti-HIV1 / 2 Plus	GEN SYS Anti-HIV 1 / 2 Lab #1	GEN SYS Anti-HIV 1 / 2 Lab #2	CAMBRIDGE BIOTECH Anti-HIV 1 Western Blot Band Patterns	CHIRON HIV 1 bDNA	RESEARCH USE PCR	ROCHE HIV 1 Monitor PCR
6247-01	03/15/97	0.14	0.086	0.203	p24	<500	<100	<400
6247-02	03/17/97	0.14	0.115	0.362	p24	<500	<100	<400
6247-03	03/22/97	0.16	0.129	0.217	p24	<500	<100	<400
6247-04	03/24/97	0.14	0.133	0.303	p24	<500	<100	<400
6247-05	03/29/97	0.15	0.119	0.242	p24	<500	<100	<400
6247-06	03/31/97	0.14	0.097	0.307	p24	<500	<100	<400
6247-07	04/05/97	0.14	0.146	0.206	p24	32,460	32,000	23,600
6247-08	04/07/97	0.13	0.193	0.144	p24	236,500	60,000	124,000
6247-09	04/12/97	5.03	0.102	0.144	p24	>800,000	500,000	675,000
6247-10	04/14/97	2.56	0.150	0.130	NO BANDS	>800,000	470,000	>750,000

Access to Clinical Specimens and Patient Populations for your Research and Product Development.